同种异体及其他创新型嵌合抗原受体平台。 - Suppr

Suppr

超能文献

Allogeneic and other innovative chimeric antigen receptor platforms.

作者信息

Jallouk Andrew P, Sengsayadeth Salyka, Savani Bipin N, Dholaria Bhagirathbhai, Oluwole Olalekan

机构信息

Medicine, Hematology Oncology Vanderbilt University Medical Center.

出版信息

Clin Hematol Int. 2024 Sep 27;6(3):61-72. doi: 10.46989/001c.121404. eCollection 2024.

DOI:10.46989/001c.121404

PMID:39351308

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11441714/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f131/11441714/a59d757b8886/chi_2024_6_3_121404_237148.jpg

相似文献

Allogeneic and other innovative chimeric antigen receptor platforms.

Clin Hematol Int. 2024 Sep 27;6(3):61-72. doi: 10.46989/001c.121404. eCollection 2024.

Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.

Cell Mol Immunol. 2021 Sep;18(9):2083-2100. doi: 10.1038/s41423-021-00732-6. Epub 2021 Jul 15.

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.

Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.

Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.

Curr Pharm Biotechnol. 2024;25(15):2001-2011. doi: 10.2174/0113892010265228231116073012.

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.

Cell Rep Med. 2021 Nov 16;2(11):100449. doi: 10.1016/j.xcrm.2021.100449.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.

Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.

Pathol Res Pract. 2024 Oct;262:155518. doi: 10.1016/j.prp.2024.155518. Epub 2024 Aug 10.

Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.

Blood. 2023 Feb 23;141(8):869-876. doi: 10.1182/blood.2022016201.

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.

Int J Mol Sci. 2023 Dec 7;24(24):17231. doi: 10.3390/ijms242417231.

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.

Tissue Eng Regen Med. 2023 Jun;20(3):371-387. doi: 10.1007/s13770-022-00515-8. Epub 2023 Mar 3.

本文引用的文献

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul 3.

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.

Blood Adv. 2023 Nov 14;7(21):6785-6789. doi: 10.1182/bloodadvances.2023010653.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.

Cancer Discov. 2023 Sep 6;13(9):1982-1997. doi: 10.1158/2159-8290.CD-22-1276.

New cell sources for CAR-based immunotherapy.

Biomark Res. 2023 May 6;11(1):49. doi: 10.1186/s40364-023-00482-9.

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.

Nat Commun. 2023 Apr 10;14(1):2020. doi: 10.1038/s41467-023-37785-2.

Unraveling barriers to iPSC-derived CAR-T cell differentiation.

Cell Stem Cell. 2023 Mar 2;30(3):248-249. doi: 10.1016/j.stem.2023.02.004.

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

J Clin Oncol. 2023 May 10;41(14):2594-2606. doi: 10.1200/JCO.22.01797. Epub 2023 Feb 8.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7. Epub 2023 Jan 23.

Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.

Nat Biotechnol. 2023 May;41(5):717-727. doi: 10.1038/s41587-022-01540-7. Epub 2023 Jan 2.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验